nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—SLC6A4—Alzheimer's disease	0.149	0.405	CbGaD
Paroxetine—HTR2A—Alzheimer's disease	0.115	0.311	CbGaD
Paroxetine—HTR2A—Donepezil—Alzheimer's disease	0.105	0.342	CbGbCtD
Paroxetine—CYP2D6—Alzheimer's disease	0.105	0.284	CbGaD
Paroxetine—CYP2B6—Memantine—Alzheimer's disease	0.0628	0.204	CbGbCtD
Paroxetine—CYP2D6—Rivastigmine—Alzheimer's disease	0.0438	0.142	CbGbCtD
Paroxetine—CYP2C9—Donepezil—Alzheimer's disease	0.0383	0.124	CbGbCtD
Paroxetine—CYP2D6—Donepezil—Alzheimer's disease	0.035	0.114	CbGbCtD
Paroxetine—CYP2D6—Galantamine—Alzheimer's disease	0.0225	0.0733	CbGbCtD
Paroxetine—SLC6A2—locus ceruleus—Alzheimer's disease	0.00496	0.1	CbGeAlD
Paroxetine—HTR2A—choroid plexus—Alzheimer's disease	0.00483	0.0977	CbGeAlD
Paroxetine—HTR2A—locus ceruleus—Alzheimer's disease	0.00298	0.0604	CbGeAlD
Paroxetine—SLC6A3—telencephalic ventricle—Alzheimer's disease	0.00292	0.0591	CbGeAlD
Paroxetine—HTR2A—cerebellar cortex—Alzheimer's disease	0.00243	0.0492	CbGeAlD
Paroxetine—TACR1—forebrain—Alzheimer's disease	0.00151	0.0307	CbGeAlD
Paroxetine—HTR2A—telencephalic ventricle—Alzheimer's disease	0.00141	0.0286	CbGeAlD
Paroxetine—TACR1—telencephalon—Alzheimer's disease	0.00139	0.0282	CbGeAlD
Paroxetine—TACR1—nervous system—Alzheimer's disease	0.000822	0.0166	CbGeAlD
Paroxetine—TACR1—central nervous system—Alzheimer's disease	0.000791	0.016	CbGeAlD
Paroxetine—CHRM4—nervous system—Alzheimer's disease	0.000773	0.0156	CbGeAlD
Paroxetine—CHRM2—forebrain—Alzheimer's disease	0.000764	0.0155	CbGeAlD
Paroxetine—SLC6A3—forebrain—Alzheimer's disease	0.000762	0.0154	CbGeAlD
Paroxetine—CHRM4—central nervous system—Alzheimer's disease	0.000744	0.0151	CbGeAlD
Paroxetine—CHRM2—telencephalon—Alzheimer's disease	0.000702	0.0142	CbGeAlD
Paroxetine—SLC6A3—telencephalon—Alzheimer's disease	0.0007	0.0142	CbGeAlD
Paroxetine—HTR2A—blood vessel—Alzheimer's disease	0.0007	0.0142	CbGeAlD
Paroxetine—SLC6A4—forebrain—Alzheimer's disease	0.000698	0.0141	CbGeAlD
Paroxetine—CHRM1—forebrain—Alzheimer's disease	0.000695	0.0141	CbGeAlD
Paroxetine—SLC6A4—telencephalon—Alzheimer's disease	0.000642	0.013	CbGeAlD
Paroxetine—CHRM1—telencephalon—Alzheimer's disease	0.000639	0.0129	CbGeAlD
Paroxetine—TACR1—brain—Alzheimer's disease	0.000628	0.0127	CbGeAlD
Paroxetine—CHRM3—forebrain—Alzheimer's disease	0.000622	0.0126	CbGeAlD
Paroxetine—SLC6A2—forebrain—Alzheimer's disease	0.000615	0.0124	CbGeAlD
Paroxetine—CHRM5—nervous system—Alzheimer's disease	0.000604	0.0122	CbGeAlD
Paroxetine—CHRM4—brain—Alzheimer's disease	0.000591	0.012	CbGeAlD
Paroxetine—CHRM5—central nervous system—Alzheimer's disease	0.000582	0.0118	CbGeAlD
Paroxetine—CHRM3—telencephalon—Alzheimer's disease	0.000572	0.0116	CbGeAlD
Paroxetine—SLC6A2—telencephalon—Alzheimer's disease	0.000565	0.0114	CbGeAlD
Paroxetine—CHRM5—brain—Alzheimer's disease	0.000462	0.00935	CbGeAlD
Paroxetine—ABCB1—blood vessel—Alzheimer's disease	0.000459	0.00929	CbGeAlD
Paroxetine—HTR2A—embryo—Alzheimer's disease	0.000418	0.00845	CbGeAlD
Paroxetine—CHRM2—nervous system—Alzheimer's disease	0.000415	0.0084	CbGeAlD
Paroxetine—SLC6A3—nervous system—Alzheimer's disease	0.000413	0.00837	CbGeAlD
Paroxetine—CHRM2—central nervous system—Alzheimer's disease	0.000399	0.00808	CbGeAlD
Paroxetine—SLC6A3—central nervous system—Alzheimer's disease	0.000398	0.00806	CbGeAlD
Paroxetine—SLC6A3—cerebellum—Alzheimer's disease	0.000389	0.00788	CbGeAlD
Paroxetine—SLC6A4—nervous system—Alzheimer's disease	0.000379	0.00767	CbGeAlD
Paroxetine—CHRM1—nervous system—Alzheimer's disease	0.000377	0.00764	CbGeAlD
Paroxetine—HTR2A—forebrain—Alzheimer's disease	0.000369	0.00748	CbGeAlD
Paroxetine—SLC6A4—central nervous system—Alzheimer's disease	0.000365	0.00739	CbGeAlD
Paroxetine—CHRM1—central nervous system—Alzheimer's disease	0.000363	0.00736	CbGeAlD
Paroxetine—HTR2A—telencephalon—Alzheimer's disease	0.00034	0.00688	CbGeAlD
Paroxetine—CHRM3—nervous system—Alzheimer's disease	0.000338	0.00684	CbGeAlD
Paroxetine—CYP2D6—forebrain—Alzheimer's disease	0.000336	0.00681	CbGeAlD
Paroxetine—SLC6A2—nervous system—Alzheimer's disease	0.000334	0.00675	CbGeAlD
Paroxetine—CHRM3—central nervous system—Alzheimer's disease	0.000325	0.00658	CbGeAlD
Paroxetine—SLC6A2—central nervous system—Alzheimer's disease	0.000321	0.0065	CbGeAlD
Paroxetine—CHRM2—brain—Alzheimer's disease	0.000317	0.00642	CbGeAlD
Paroxetine—SLC6A3—brain—Alzheimer's disease	0.000316	0.0064	CbGeAlD
Paroxetine—CYP2D6—telencephalon—Alzheimer's disease	0.000309	0.00626	CbGeAlD
Paroxetine—SLC6A4—brain—Alzheimer's disease	0.00029	0.00586	CbGeAlD
Paroxetine—CHRM1—brain—Alzheimer's disease	0.000289	0.00584	CbGeAlD
Paroxetine—ABCB1—embryo—Alzheimer's disease	0.000274	0.00554	CbGeAlD
Paroxetine—CHRM3—brain—Alzheimer's disease	0.000258	0.00523	CbGeAlD
Paroxetine—SLC6A2—brain—Alzheimer's disease	0.000255	0.00516	CbGeAlD
Paroxetine—CYP2B6—nervous system—Alzheimer's disease	0.000246	0.00498	CbGeAlD
Paroxetine—ABCB1—forebrain—Alzheimer's disease	0.000242	0.0049	CbGeAlD
Paroxetine—CYP2B6—central nervous system—Alzheimer's disease	0.000237	0.00479	CbGeAlD
Paroxetine—ABCB1—telencephalon—Alzheimer's disease	0.000223	0.00451	CbGeAlD
Paroxetine—CYP2C8—brain—Alzheimer's disease	0.000209	0.00424	CbGeAlD
Paroxetine—HTR2A—nervous system—Alzheimer's disease	0.000201	0.00406	CbGeAlD
Paroxetine—HTR2A—central nervous system—Alzheimer's disease	0.000193	0.00391	CbGeAlD
Paroxetine—HTR2A—cerebellum—Alzheimer's disease	0.000189	0.00382	CbGeAlD
Paroxetine—CYP2B6—brain—Alzheimer's disease	0.000188	0.0038	CbGeAlD
Paroxetine—CYP2D6—nervous system—Alzheimer's disease	0.000183	0.0037	CbGeAlD
Paroxetine—CYP2D6—central nervous system—Alzheimer's disease	0.000176	0.00356	CbGeAlD
Paroxetine—CYP2D6—cerebellum—Alzheimer's disease	0.000172	0.00348	CbGeAlD
Paroxetine—HTR2A—brain—Alzheimer's disease	0.000153	0.0031	CbGeAlD
Paroxetine—CYP2D6—brain—Alzheimer's disease	0.00014	0.00283	CbGeAlD
Paroxetine—ABCB1—nervous system—Alzheimer's disease	0.000131	0.00266	CbGeAlD
Paroxetine—ABCB1—central nervous system—Alzheimer's disease	0.000126	0.00256	CbGeAlD
Paroxetine—ABCB1—cerebellum—Alzheimer's disease	0.000124	0.0025	CbGeAlD
Paroxetine—Oedema peripheral—Memantine—Alzheimer's disease	0.000101	0.000482	CcSEcCtD
Paroxetine—Arrhythmia—Donepezil—Alzheimer's disease	0.000101	0.000482	CcSEcCtD
Paroxetine—Haemoglobin—Rivastigmine—Alzheimer's disease	0.000101	0.000481	CcSEcCtD
Paroxetine—Connective tissue disorder—Memantine—Alzheimer's disease	0.000101	0.000481	CcSEcCtD
Paroxetine—Rhinitis—Rivastigmine—Alzheimer's disease	0.000101	0.00048	CcSEcCtD
Paroxetine—Skin disorder—Galantamine—Alzheimer's disease	0.000101	0.00048	CcSEcCtD
Paroxetine—Haemorrhage—Rivastigmine—Alzheimer's disease	0.000101	0.000479	CcSEcCtD
Paroxetine—Hepatitis—Rivastigmine—Alzheimer's disease	0.000101	0.000479	CcSEcCtD
Paroxetine—ABCB1—brain—Alzheimer's disease	0.0001	0.00203	CbGeAlD
Paroxetine—Hyperhidrosis—Galantamine—Alzheimer's disease	0.0001	0.000478	CcSEcCtD
Paroxetine—Hallucination—Rivastigmine—Alzheimer's disease	0.0001	0.000477	CcSEcCtD
Paroxetine—Hypoaesthesia—Rivastigmine—Alzheimer's disease	0.0001	0.000477	CcSEcCtD
Paroxetine—Alopecia—Donepezil—Alzheimer's disease	0.0001	0.000477	CcSEcCtD
Paroxetine—Pharyngitis—Rivastigmine—Alzheimer's disease	9.98e-05	0.000475	CcSEcCtD
Paroxetine—Mental disorder—Donepezil—Alzheimer's disease	9.91e-05	0.000472	CcSEcCtD
Paroxetine—Oedema peripheral—Rivastigmine—Alzheimer's disease	9.9e-05	0.000472	CcSEcCtD
Paroxetine—Visual impairment—Memantine—Alzheimer's disease	9.9e-05	0.000472	CcSEcCtD
Paroxetine—Connective tissue disorder—Rivastigmine—Alzheimer's disease	9.88e-05	0.000471	CcSEcCtD
Paroxetine—Malnutrition—Donepezil—Alzheimer's disease	9.85e-05	0.000469	CcSEcCtD
Paroxetine—Erythema—Donepezil—Alzheimer's disease	9.85e-05	0.000469	CcSEcCtD
Paroxetine—Erythema multiforme—Memantine—Alzheimer's disease	9.71e-05	0.000463	CcSEcCtD
Paroxetine—Flatulence—Donepezil—Alzheimer's disease	9.71e-05	0.000463	CcSEcCtD
Paroxetine—Hypotension—Galantamine—Alzheimer's disease	9.69e-05	0.000462	CcSEcCtD
Paroxetine—Visual impairment—Rivastigmine—Alzheimer's disease	9.69e-05	0.000462	CcSEcCtD
Paroxetine—Tension—Donepezil—Alzheimer's disease	9.67e-05	0.000461	CcSEcCtD
Paroxetine—Dysgeusia—Donepezil—Alzheimer's disease	9.65e-05	0.00046	CcSEcCtD
Paroxetine—Eye disorder—Memantine—Alzheimer's disease	9.6e-05	0.000458	CcSEcCtD
Paroxetine—Tinnitus—Memantine—Alzheimer's disease	9.58e-05	0.000457	CcSEcCtD
Paroxetine—Nervousness—Donepezil—Alzheimer's disease	9.57e-05	0.000456	CcSEcCtD
Paroxetine—Cardiac disorder—Memantine—Alzheimer's disease	9.53e-05	0.000454	CcSEcCtD
Paroxetine—Flushing—Memantine—Alzheimer's disease	9.53e-05	0.000454	CcSEcCtD
Paroxetine—Back pain—Donepezil—Alzheimer's disease	9.53e-05	0.000454	CcSEcCtD
Paroxetine—Erythema multiforme—Rivastigmine—Alzheimer's disease	9.5e-05	0.000453	CcSEcCtD
Paroxetine—Muscle spasms—Donepezil—Alzheimer's disease	9.47e-05	0.000451	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Galantamine—Alzheimer's disease	9.45e-05	0.00045	CcSEcCtD
Paroxetine—Eye disorder—Rivastigmine—Alzheimer's disease	9.39e-05	0.000448	CcSEcCtD
Paroxetine—Insomnia—Galantamine—Alzheimer's disease	9.38e-05	0.000447	CcSEcCtD
Paroxetine—Tinnitus—Rivastigmine—Alzheimer's disease	9.37e-05	0.000447	CcSEcCtD
Paroxetine—Flushing—Rivastigmine—Alzheimer's disease	9.33e-05	0.000445	CcSEcCtD
Paroxetine—Cardiac disorder—Rivastigmine—Alzheimer's disease	9.33e-05	0.000445	CcSEcCtD
Paroxetine—Angiopathy—Memantine—Alzheimer's disease	9.32e-05	0.000444	CcSEcCtD
Paroxetine—Paraesthesia—Galantamine—Alzheimer's disease	9.31e-05	0.000444	CcSEcCtD
Paroxetine—Vision blurred—Donepezil—Alzheimer's disease	9.28e-05	0.000442	CcSEcCtD
Paroxetine—Immune system disorder—Memantine—Alzheimer's disease	9.28e-05	0.000442	CcSEcCtD
Paroxetine—Mediastinal disorder—Memantine—Alzheimer's disease	9.26e-05	0.000441	CcSEcCtD
Paroxetine—Tremor—Donepezil—Alzheimer's disease	9.23e-05	0.00044	CcSEcCtD
Paroxetine—Somnolence—Galantamine—Alzheimer's disease	9.22e-05	0.000439	CcSEcCtD
Paroxetine—Chills—Memantine—Alzheimer's disease	9.22e-05	0.000439	CcSEcCtD
Paroxetine—Arrhythmia—Memantine—Alzheimer's disease	9.18e-05	0.000437	CcSEcCtD
Paroxetine—Ill-defined disorder—Donepezil—Alzheimer's disease	9.14e-05	0.000436	CcSEcCtD
Paroxetine—Dyspepsia—Galantamine—Alzheimer's disease	9.13e-05	0.000435	CcSEcCtD
Paroxetine—Angiopathy—Rivastigmine—Alzheimer's disease	9.12e-05	0.000435	CcSEcCtD
Paroxetine—Anaemia—Donepezil—Alzheimer's disease	9.1e-05	0.000434	CcSEcCtD
Paroxetine—Alopecia—Memantine—Alzheimer's disease	9.08e-05	0.000433	CcSEcCtD
Paroxetine—Mediastinal disorder—Rivastigmine—Alzheimer's disease	9.06e-05	0.000432	CcSEcCtD
Paroxetine—Agitation—Donepezil—Alzheimer's disease	9.05e-05	0.000431	CcSEcCtD
Paroxetine—Chills—Rivastigmine—Alzheimer's disease	9.02e-05	0.00043	CcSEcCtD
Paroxetine—Decreased appetite—Galantamine—Alzheimer's disease	9.02e-05	0.00043	CcSEcCtD
Paroxetine—Mental disorder—Memantine—Alzheimer's disease	9e-05	0.000429	CcSEcCtD
Paroxetine—Arrhythmia—Rivastigmine—Alzheimer's disease	8.98e-05	0.000428	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Galantamine—Alzheimer's disease	8.96e-05	0.000427	CcSEcCtD
Paroxetine—Malnutrition—Memantine—Alzheimer's disease	8.94e-05	0.000426	CcSEcCtD
Paroxetine—Fatigue—Galantamine—Alzheimer's disease	8.94e-05	0.000426	CcSEcCtD
Paroxetine—Malaise—Donepezil—Alzheimer's disease	8.88e-05	0.000423	CcSEcCtD
Paroxetine—Alopecia—Rivastigmine—Alzheimer's disease	8.88e-05	0.000423	CcSEcCtD
Paroxetine—Constipation—Galantamine—Alzheimer's disease	8.87e-05	0.000423	CcSEcCtD
Paroxetine—Vertigo—Donepezil—Alzheimer's disease	8.85e-05	0.000422	CcSEcCtD
Paroxetine—Syncope—Donepezil—Alzheimer's disease	8.83e-05	0.000421	CcSEcCtD
Paroxetine—Flatulence—Memantine—Alzheimer's disease	8.81e-05	0.00042	CcSEcCtD
Paroxetine—Mental disorder—Rivastigmine—Alzheimer's disease	8.81e-05	0.00042	CcSEcCtD
Paroxetine—Tension—Memantine—Alzheimer's disease	8.78e-05	0.000418	CcSEcCtD
Paroxetine—Dysgeusia—Memantine—Alzheimer's disease	8.76e-05	0.000417	CcSEcCtD
Paroxetine—Erythema—Rivastigmine—Alzheimer's disease	8.75e-05	0.000417	CcSEcCtD
Paroxetine—Malnutrition—Rivastigmine—Alzheimer's disease	8.75e-05	0.000417	CcSEcCtD
Paroxetine—Nervousness—Memantine—Alzheimer's disease	8.69e-05	0.000414	CcSEcCtD
Paroxetine—Loss of consciousness—Donepezil—Alzheimer's disease	8.66e-05	0.000413	CcSEcCtD
Paroxetine—Back pain—Memantine—Alzheimer's disease	8.65e-05	0.000412	CcSEcCtD
Paroxetine—Flatulence—Rivastigmine—Alzheimer's disease	8.62e-05	0.000411	CcSEcCtD
Paroxetine—Cough—Donepezil—Alzheimer's disease	8.6e-05	0.00041	CcSEcCtD
Paroxetine—Tension—Rivastigmine—Alzheimer's disease	8.59e-05	0.000409	CcSEcCtD
Paroxetine—Dysgeusia—Rivastigmine—Alzheimer's disease	8.57e-05	0.000408	CcSEcCtD
Paroxetine—Feeling abnormal—Galantamine—Alzheimer's disease	8.55e-05	0.000407	CcSEcCtD
Paroxetine—Convulsion—Donepezil—Alzheimer's disease	8.53e-05	0.000407	CcSEcCtD
Paroxetine—Hypertension—Donepezil—Alzheimer's disease	8.5e-05	0.000405	CcSEcCtD
Paroxetine—Nervousness—Rivastigmine—Alzheimer's disease	8.5e-05	0.000405	CcSEcCtD
Paroxetine—Gastrointestinal pain—Galantamine—Alzheimer's disease	8.48e-05	0.000404	CcSEcCtD
Paroxetine—Back pain—Rivastigmine—Alzheimer's disease	8.46e-05	0.000403	CcSEcCtD
Paroxetine—Vision blurred—Memantine—Alzheimer's disease	8.43e-05	0.000402	CcSEcCtD
Paroxetine—Muscle spasms—Rivastigmine—Alzheimer's disease	8.41e-05	0.000401	CcSEcCtD
Paroxetine—Arthralgia—Donepezil—Alzheimer's disease	8.39e-05	0.0004	CcSEcCtD
Paroxetine—Myalgia—Donepezil—Alzheimer's disease	8.39e-05	0.0004	CcSEcCtD
Paroxetine—Chest pain—Donepezil—Alzheimer's disease	8.39e-05	0.0004	CcSEcCtD
Paroxetine—Tremor—Memantine—Alzheimer's disease	8.38e-05	0.000399	CcSEcCtD
Paroxetine—Anxiety—Donepezil—Alzheimer's disease	8.36e-05	0.000398	CcSEcCtD
Paroxetine—Ill-defined disorder—Memantine—Alzheimer's disease	8.3e-05	0.000395	CcSEcCtD
Paroxetine—Discomfort—Donepezil—Alzheimer's disease	8.29e-05	0.000395	CcSEcCtD
Paroxetine—Anaemia—Memantine—Alzheimer's disease	8.27e-05	0.000394	CcSEcCtD
Paroxetine—Vision blurred—Rivastigmine—Alzheimer's disease	8.25e-05	0.000393	CcSEcCtD
Paroxetine—Agitation—Memantine—Alzheimer's disease	8.22e-05	0.000392	CcSEcCtD
Paroxetine—Dry mouth—Donepezil—Alzheimer's disease	8.2e-05	0.000391	CcSEcCtD
Paroxetine—Abdominal pain—Galantamine—Alzheimer's disease	8.2e-05	0.000391	CcSEcCtD
Paroxetine—Body temperature increased—Galantamine—Alzheimer's disease	8.2e-05	0.000391	CcSEcCtD
Paroxetine—Tremor—Rivastigmine—Alzheimer's disease	8.2e-05	0.000391	CcSEcCtD
Paroxetine—Ill-defined disorder—Rivastigmine—Alzheimer's disease	8.12e-05	0.000387	CcSEcCtD
Paroxetine—Confusional state—Donepezil—Alzheimer's disease	8.11e-05	0.000386	CcSEcCtD
Paroxetine—Anaemia—Rivastigmine—Alzheimer's disease	8.09e-05	0.000385	CcSEcCtD
Paroxetine—Malaise—Memantine—Alzheimer's disease	8.07e-05	0.000384	CcSEcCtD
Paroxetine—Agitation—Rivastigmine—Alzheimer's disease	8.04e-05	0.000383	CcSEcCtD
Paroxetine—Oedema—Donepezil—Alzheimer's disease	8.04e-05	0.000383	CcSEcCtD
Paroxetine—Vertigo—Memantine—Alzheimer's disease	8.04e-05	0.000383	CcSEcCtD
Paroxetine—Syncope—Memantine—Alzheimer's disease	8.02e-05	0.000382	CcSEcCtD
Paroxetine—Leukopenia—Memantine—Alzheimer's disease	8.01e-05	0.000382	CcSEcCtD
Paroxetine—Infection—Donepezil—Alzheimer's disease	7.99e-05	0.000381	CcSEcCtD
Paroxetine—Shock—Donepezil—Alzheimer's disease	7.91e-05	0.000377	CcSEcCtD
Paroxetine—Palpitations—Memantine—Alzheimer's disease	7.9e-05	0.000377	CcSEcCtD
Paroxetine—Malaise—Rivastigmine—Alzheimer's disease	7.89e-05	0.000376	CcSEcCtD
Paroxetine—Nervous system disorder—Donepezil—Alzheimer's disease	7.88e-05	0.000376	CcSEcCtD
Paroxetine—Thrombocytopenia—Donepezil—Alzheimer's disease	7.87e-05	0.000375	CcSEcCtD
Paroxetine—Vertigo—Rivastigmine—Alzheimer's disease	7.86e-05	0.000375	CcSEcCtD
Paroxetine—Loss of consciousness—Memantine—Alzheimer's disease	7.86e-05	0.000375	CcSEcCtD
Paroxetine—Syncope—Rivastigmine—Alzheimer's disease	7.85e-05	0.000374	CcSEcCtD
Paroxetine—Cough—Memantine—Alzheimer's disease	7.8e-05	0.000372	CcSEcCtD
Paroxetine—Hyperhidrosis—Donepezil—Alzheimer's disease	7.77e-05	0.00037	CcSEcCtD
Paroxetine—Convulsion—Memantine—Alzheimer's disease	7.75e-05	0.000369	CcSEcCtD
Paroxetine—Palpitations—Rivastigmine—Alzheimer's disease	7.73e-05	0.000368	CcSEcCtD
Paroxetine—Hypertension—Memantine—Alzheimer's disease	7.72e-05	0.000368	CcSEcCtD
Paroxetine—Loss of consciousness—Rivastigmine—Alzheimer's disease	7.69e-05	0.000366	CcSEcCtD
Paroxetine—Hypersensitivity—Galantamine—Alzheimer's disease	7.64e-05	0.000364	CcSEcCtD
Paroxetine—Cough—Rivastigmine—Alzheimer's disease	7.63e-05	0.000364	CcSEcCtD
Paroxetine—Myalgia—Memantine—Alzheimer's disease	7.61e-05	0.000363	CcSEcCtD
Paroxetine—Chest pain—Memantine—Alzheimer's disease	7.61e-05	0.000363	CcSEcCtD
Paroxetine—Arthralgia—Memantine—Alzheimer's disease	7.61e-05	0.000363	CcSEcCtD
Paroxetine—Anxiety—Memantine—Alzheimer's disease	7.59e-05	0.000362	CcSEcCtD
Paroxetine—Convulsion—Rivastigmine—Alzheimer's disease	7.58e-05	0.000361	CcSEcCtD
Paroxetine—Hypertension—Rivastigmine—Alzheimer's disease	7.55e-05	0.00036	CcSEcCtD
Paroxetine—Discomfort—Memantine—Alzheimer's disease	7.52e-05	0.000359	CcSEcCtD
Paroxetine—Hypotension—Donepezil—Alzheimer's disease	7.51e-05	0.000358	CcSEcCtD
Paroxetine—Chest pain—Rivastigmine—Alzheimer's disease	7.45e-05	0.000355	CcSEcCtD
Paroxetine—Arthralgia—Rivastigmine—Alzheimer's disease	7.45e-05	0.000355	CcSEcCtD
Paroxetine—Myalgia—Rivastigmine—Alzheimer's disease	7.45e-05	0.000355	CcSEcCtD
Paroxetine—Dry mouth—Memantine—Alzheimer's disease	7.45e-05	0.000355	CcSEcCtD
Paroxetine—Asthenia—Galantamine—Alzheimer's disease	7.44e-05	0.000355	CcSEcCtD
Paroxetine—Anxiety—Rivastigmine—Alzheimer's disease	7.42e-05	0.000354	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Rivastigmine—Alzheimer's disease	7.4e-05	0.000353	CcSEcCtD
Paroxetine—Confusional state—Memantine—Alzheimer's disease	7.36e-05	0.000351	CcSEcCtD
Paroxetine—Discomfort—Rivastigmine—Alzheimer's disease	7.36e-05	0.000351	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Donepezil—Alzheimer's disease	7.32e-05	0.000349	CcSEcCtD
Paroxetine—Oedema—Memantine—Alzheimer's disease	7.3e-05	0.000348	CcSEcCtD
Paroxetine—Dry mouth—Rivastigmine—Alzheimer's disease	7.28e-05	0.000347	CcSEcCtD
Paroxetine—Insomnia—Donepezil—Alzheimer's disease	7.27e-05	0.000347	CcSEcCtD
Paroxetine—Infection—Memantine—Alzheimer's disease	7.25e-05	0.000346	CcSEcCtD
Paroxetine—Paraesthesia—Donepezil—Alzheimer's disease	7.22e-05	0.000344	CcSEcCtD
Paroxetine—Confusional state—Rivastigmine—Alzheimer's disease	7.2e-05	0.000343	CcSEcCtD
Paroxetine—Shock—Memantine—Alzheimer's disease	7.18e-05	0.000342	CcSEcCtD
Paroxetine—Dyspnoea—Donepezil—Alzheimer's disease	7.17e-05	0.000342	CcSEcCtD
Paroxetine—Nervous system disorder—Memantine—Alzheimer's disease	7.16e-05	0.000341	CcSEcCtD
Paroxetine—Somnolence—Donepezil—Alzheimer's disease	7.15e-05	0.000341	CcSEcCtD
Paroxetine—Thrombocytopenia—Memantine—Alzheimer's disease	7.15e-05	0.000341	CcSEcCtD
Paroxetine—Oedema—Rivastigmine—Alzheimer's disease	7.14e-05	0.00034	CcSEcCtD
Paroxetine—Tachycardia—Memantine—Alzheimer's disease	7.12e-05	0.00034	CcSEcCtD
Paroxetine—Diarrhoea—Galantamine—Alzheimer's disease	7.1e-05	0.000338	CcSEcCtD
Paroxetine—Infection—Rivastigmine—Alzheimer's disease	7.09e-05	0.000338	CcSEcCtD
Paroxetine—Skin disorder—Memantine—Alzheimer's disease	7.09e-05	0.000338	CcSEcCtD
Paroxetine—Dyspepsia—Donepezil—Alzheimer's disease	7.08e-05	0.000337	CcSEcCtD
Paroxetine—Hyperhidrosis—Memantine—Alzheimer's disease	7.06e-05	0.000336	CcSEcCtD
Paroxetine—Shock—Rivastigmine—Alzheimer's disease	7.03e-05	0.000335	CcSEcCtD
Paroxetine—Nervous system disorder—Rivastigmine—Alzheimer's disease	7e-05	0.000334	CcSEcCtD
Paroxetine—Thrombocytopenia—Rivastigmine—Alzheimer's disease	6.99e-05	0.000333	CcSEcCtD
Paroxetine—Decreased appetite—Donepezil—Alzheimer's disease	6.99e-05	0.000333	CcSEcCtD
Paroxetine—Tachycardia—Rivastigmine—Alzheimer's disease	6.97e-05	0.000332	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Donepezil—Alzheimer's disease	6.94e-05	0.000331	CcSEcCtD
Paroxetine—Skin disorder—Rivastigmine—Alzheimer's disease	6.94e-05	0.000331	CcSEcCtD
Paroxetine—Fatigue—Donepezil—Alzheimer's disease	6.93e-05	0.00033	CcSEcCtD
Paroxetine—Hyperhidrosis—Rivastigmine—Alzheimer's disease	6.9e-05	0.000329	CcSEcCtD
Paroxetine—Pain—Donepezil—Alzheimer's disease	6.87e-05	0.000328	CcSEcCtD
Paroxetine—Constipation—Donepezil—Alzheimer's disease	6.87e-05	0.000328	CcSEcCtD
Paroxetine—Dizziness—Galantamine—Alzheimer's disease	6.86e-05	0.000327	CcSEcCtD
Paroxetine—Hypotension—Memantine—Alzheimer's disease	6.82e-05	0.000325	CcSEcCtD
Paroxetine—Hypotension—Rivastigmine—Alzheimer's disease	6.67e-05	0.000318	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Memantine—Alzheimer's disease	6.65e-05	0.000317	CcSEcCtD
Paroxetine—Feeling abnormal—Donepezil—Alzheimer's disease	6.62e-05	0.000316	CcSEcCtD
Paroxetine—Insomnia—Memantine—Alzheimer's disease	6.6e-05	0.000315	CcSEcCtD
Paroxetine—Vomiting—Galantamine—Alzheimer's disease	6.6e-05	0.000314	CcSEcCtD
Paroxetine—Gastrointestinal pain—Donepezil—Alzheimer's disease	6.57e-05	0.000313	CcSEcCtD
Paroxetine—Paraesthesia—Memantine—Alzheimer's disease	6.55e-05	0.000312	CcSEcCtD
Paroxetine—Rash—Galantamine—Alzheimer's disease	6.54e-05	0.000312	CcSEcCtD
Paroxetine—Dermatitis—Galantamine—Alzheimer's disease	6.53e-05	0.000311	CcSEcCtD
Paroxetine—Dyspnoea—Memantine—Alzheimer's disease	6.51e-05	0.00031	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Rivastigmine—Alzheimer's disease	6.51e-05	0.00031	CcSEcCtD
Paroxetine—Headache—Galantamine—Alzheimer's disease	6.5e-05	0.00031	CcSEcCtD
Paroxetine—Somnolence—Memantine—Alzheimer's disease	6.49e-05	0.000309	CcSEcCtD
Paroxetine—Insomnia—Rivastigmine—Alzheimer's disease	6.46e-05	0.000308	CcSEcCtD
Paroxetine—Dyspepsia—Memantine—Alzheimer's disease	6.43e-05	0.000306	CcSEcCtD
Paroxetine—Paraesthesia—Rivastigmine—Alzheimer's disease	6.41e-05	0.000306	CcSEcCtD
Paroxetine—Urticaria—Donepezil—Alzheimer's disease	6.39e-05	0.000304	CcSEcCtD
Paroxetine—Dyspnoea—Rivastigmine—Alzheimer's disease	6.37e-05	0.000303	CcSEcCtD
Paroxetine—Body temperature increased—Donepezil—Alzheimer's disease	6.35e-05	0.000303	CcSEcCtD
Paroxetine—Abdominal pain—Donepezil—Alzheimer's disease	6.35e-05	0.000303	CcSEcCtD
Paroxetine—Somnolence—Rivastigmine—Alzheimer's disease	6.35e-05	0.000303	CcSEcCtD
Paroxetine—Decreased appetite—Memantine—Alzheimer's disease	6.35e-05	0.000302	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Memantine—Alzheimer's disease	6.3e-05	0.0003	CcSEcCtD
Paroxetine—Fatigue—Memantine—Alzheimer's disease	6.29e-05	0.0003	CcSEcCtD
Paroxetine—Dyspepsia—Rivastigmine—Alzheimer's disease	6.29e-05	0.0003	CcSEcCtD
Paroxetine—Constipation—Memantine—Alzheimer's disease	6.24e-05	0.000297	CcSEcCtD
Paroxetine—Pain—Memantine—Alzheimer's disease	6.24e-05	0.000297	CcSEcCtD
Paroxetine—Decreased appetite—Rivastigmine—Alzheimer's disease	6.21e-05	0.000296	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Rivastigmine—Alzheimer's disease	6.16e-05	0.000294	CcSEcCtD
Paroxetine—Nausea—Galantamine—Alzheimer's disease	6.16e-05	0.000294	CcSEcCtD
Paroxetine—Fatigue—Rivastigmine—Alzheimer's disease	6.16e-05	0.000293	CcSEcCtD
Paroxetine—Constipation—Rivastigmine—Alzheimer's disease	6.11e-05	0.000291	CcSEcCtD
Paroxetine—Pain—Rivastigmine—Alzheimer's disease	6.11e-05	0.000291	CcSEcCtD
Paroxetine—Feeling abnormal—Memantine—Alzheimer's disease	6.01e-05	0.000287	CcSEcCtD
Paroxetine—Gastrointestinal pain—Memantine—Alzheimer's disease	5.97e-05	0.000284	CcSEcCtD
Paroxetine—Hypersensitivity—Donepezil—Alzheimer's disease	5.92e-05	0.000282	CcSEcCtD
Paroxetine—Feeling abnormal—Rivastigmine—Alzheimer's disease	5.88e-05	0.00028	CcSEcCtD
Paroxetine—Gastrointestinal pain—Rivastigmine—Alzheimer's disease	5.84e-05	0.000278	CcSEcCtD
Paroxetine—Urticaria—Memantine—Alzheimer's disease	5.8e-05	0.000276	CcSEcCtD
Paroxetine—Abdominal pain—Memantine—Alzheimer's disease	5.77e-05	0.000275	CcSEcCtD
Paroxetine—Body temperature increased—Memantine—Alzheimer's disease	5.77e-05	0.000275	CcSEcCtD
Paroxetine—Asthenia—Donepezil—Alzheimer's disease	5.77e-05	0.000275	CcSEcCtD
Paroxetine—Pruritus—Donepezil—Alzheimer's disease	5.69e-05	0.000271	CcSEcCtD
Paroxetine—Urticaria—Rivastigmine—Alzheimer's disease	5.67e-05	0.00027	CcSEcCtD
Paroxetine—Body temperature increased—Rivastigmine—Alzheimer's disease	5.64e-05	0.000269	CcSEcCtD
Paroxetine—Abdominal pain—Rivastigmine—Alzheimer's disease	5.64e-05	0.000269	CcSEcCtD
Paroxetine—Diarrhoea—Donepezil—Alzheimer's disease	5.5e-05	0.000262	CcSEcCtD
Paroxetine—Hypersensitivity—Memantine—Alzheimer's disease	5.38e-05	0.000256	CcSEcCtD
Paroxetine—Dizziness—Donepezil—Alzheimer's disease	5.32e-05	0.000253	CcSEcCtD
Paroxetine—Hypersensitivity—Rivastigmine—Alzheimer's disease	5.26e-05	0.000251	CcSEcCtD
Paroxetine—Asthenia—Memantine—Alzheimer's disease	5.24e-05	0.00025	CcSEcCtD
Paroxetine—Pruritus—Memantine—Alzheimer's disease	5.16e-05	0.000246	CcSEcCtD
Paroxetine—Asthenia—Rivastigmine—Alzheimer's disease	5.12e-05	0.000244	CcSEcCtD
Paroxetine—Vomiting—Donepezil—Alzheimer's disease	5.11e-05	0.000244	CcSEcCtD
Paroxetine—Rash—Donepezil—Alzheimer's disease	5.07e-05	0.000242	CcSEcCtD
Paroxetine—Dermatitis—Donepezil—Alzheimer's disease	5.06e-05	0.000241	CcSEcCtD
Paroxetine—Pruritus—Rivastigmine—Alzheimer's disease	5.05e-05	0.000241	CcSEcCtD
Paroxetine—Headache—Donepezil—Alzheimer's disease	5.04e-05	0.00024	CcSEcCtD
Paroxetine—Diarrhoea—Memantine—Alzheimer's disease	4.99e-05	0.000238	CcSEcCtD
Paroxetine—Diarrhoea—Rivastigmine—Alzheimer's disease	4.89e-05	0.000233	CcSEcCtD
Paroxetine—Dizziness—Memantine—Alzheimer's disease	4.83e-05	0.00023	CcSEcCtD
Paroxetine—Nausea—Donepezil—Alzheimer's disease	4.78e-05	0.000228	CcSEcCtD
Paroxetine—Dizziness—Rivastigmine—Alzheimer's disease	4.72e-05	0.000225	CcSEcCtD
Paroxetine—Vomiting—Memantine—Alzheimer's disease	4.64e-05	0.000221	CcSEcCtD
Paroxetine—Rash—Memantine—Alzheimer's disease	4.6e-05	0.000219	CcSEcCtD
Paroxetine—Dermatitis—Memantine—Alzheimer's disease	4.6e-05	0.000219	CcSEcCtD
Paroxetine—Headache—Memantine—Alzheimer's disease	4.57e-05	0.000218	CcSEcCtD
Paroxetine—Vomiting—Rivastigmine—Alzheimer's disease	4.54e-05	0.000216	CcSEcCtD
Paroxetine—Rash—Rivastigmine—Alzheimer's disease	4.5e-05	0.000215	CcSEcCtD
Paroxetine—Dermatitis—Rivastigmine—Alzheimer's disease	4.5e-05	0.000214	CcSEcCtD
Paroxetine—Headache—Rivastigmine—Alzheimer's disease	4.47e-05	0.000213	CcSEcCtD
Paroxetine—Nausea—Memantine—Alzheimer's disease	4.34e-05	0.000207	CcSEcCtD
Paroxetine—Nausea—Rivastigmine—Alzheimer's disease	4.24e-05	0.000202	CcSEcCtD
Paroxetine—CYP2D6—Metabolism—INPP5D—Alzheimer's disease	5.23e-06	8.08e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PPARGC1A—Alzheimer's disease	5.23e-06	8.08e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—F2—Alzheimer's disease	5.21e-06	8.05e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—HMOX1—Alzheimer's disease	5.2e-06	8.04e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	5.2e-06	8.03e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—S100B—Alzheimer's disease	5.19e-06	8.02e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—INPP5D—Alzheimer's disease	5.18e-06	8.01e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYP2D6—Alzheimer's disease	5.16e-06	7.97e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ABCA1—Alzheimer's disease	5.13e-06	7.93e-05	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TP53—Alzheimer's disease	5.12e-06	7.92e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NOTCH1—Alzheimer's disease	5.1e-06	7.88e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IGF2—Alzheimer's disease	5.03e-06	7.78e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IGF2—Alzheimer's disease	5.01e-06	7.74e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—GSK3B—Alzheimer's disease	5e-06	7.72e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IGF2—Alzheimer's disease	4.99e-06	7.71e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—MTHFR—Alzheimer's disease	4.98e-06	7.7e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ENO1—Alzheimer's disease	4.96e-06	7.66e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTGS1—Alzheimer's disease	4.96e-06	7.66e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CREB1—Alzheimer's disease	4.96e-06	7.66e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IGF2—Alzheimer's disease	4.94e-06	7.64e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—INS—Alzheimer's disease	4.93e-06	7.62e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTGS1—Alzheimer's disease	4.91e-06	7.59e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ENO1—Alzheimer's disease	4.91e-06	7.59e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—BCHE—Alzheimer's disease	4.89e-06	7.56e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IGF1R—Alzheimer's disease	4.87e-06	7.52e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCL2—Alzheimer's disease	4.85e-06	7.49e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IGF1R—Alzheimer's disease	4.84e-06	7.48e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IGF1R—Alzheimer's disease	4.83e-06	7.46e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP2D6—Alzheimer's disease	4.82e-06	7.45e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—GSK3B—Alzheimer's disease	4.78e-06	7.39e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IGF1R—Alzheimer's disease	4.78e-06	7.38e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IGF1—Alzheimer's disease	4.77e-06	7.37e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—LPL—Alzheimer's disease	4.76e-06	7.35e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CREB1—Alzheimer's disease	4.75e-06	7.33e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—INS—Alzheimer's disease	4.72e-06	7.29e-05	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—IL6—Alzheimer's disease	4.69e-06	7.25e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—LPL—Alzheimer's disease	4.67e-06	7.21e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CALM1—Alzheimer's disease	4.65e-06	7.19e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCL2—Alzheimer's disease	4.64e-06	7.18e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—LPL—Alzheimer's disease	4.64e-06	7.17e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—APOE—Alzheimer's disease	4.64e-06	7.17e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—LPL—Alzheimer's disease	4.63e-06	7.15e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MEF2C—Alzheimer's disease	4.62e-06	7.14e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PLCB1—Alzheimer's disease	4.62e-06	7.13e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—BCHE—Alzheimer's disease	4.61e-06	7.12e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MEF2C—Alzheimer's disease	4.6e-06	7.11e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CAV1—Alzheimer's disease	4.59e-06	7.1e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MEF2C—Alzheimer's disease	4.58e-06	7.08e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—LPL—Alzheimer's disease	4.58e-06	7.08e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—BCHE—Alzheimer's disease	4.57e-06	7.06e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IGF1—Alzheimer's disease	4.57e-06	7.05e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MEF2C—Alzheimer's disease	4.54e-06	7.02e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PRKCG—Alzheimer's disease	4.54e-06	7.01e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PRKCG—Alzheimer's disease	4.51e-06	6.97e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PRKCG—Alzheimer's disease	4.5e-06	6.95e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ABCA1—Alzheimer's disease	4.47e-06	6.91e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PRKCG—Alzheimer's disease	4.45e-06	6.88e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PPARGC1A—Alzheimer's disease	4.43e-06	6.84e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NGF—Alzheimer's disease	4.42e-06	6.83e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—HMOX1—Alzheimer's disease	4.41e-06	6.81e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NGF—Alzheimer's disease	4.4e-06	6.79e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NGF—Alzheimer's disease	4.38e-06	6.77e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PLCB1—Alzheimer's disease	4.35e-06	6.72e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NGF—Alzheimer's disease	4.34e-06	6.7e-05	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—AKT1—Alzheimer's disease	4.33e-06	6.69e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NOS3—Alzheimer's disease	4.32e-06	6.68e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PLCB1—Alzheimer's disease	4.31e-06	6.66e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCR5—Alzheimer's disease	4.3e-06	6.64e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—MTHFR—Alzheimer's disease	4.29e-06	6.62e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCR5—Alzheimer's disease	4.28e-06	6.61e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCR5—Alzheimer's disease	4.26e-06	6.59e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	4.23e-06	6.54e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCR5—Alzheimer's disease	4.22e-06	6.52e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ABCA1—Alzheimer's disease	4.22e-06	6.51e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HTR2A—Alzheimer's disease	4.18e-06	6.47e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ABCA1—Alzheimer's disease	4.18e-06	6.46e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HTR2A—Alzheimer's disease	4.17e-06	6.44e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NOS3—Alzheimer's disease	4.14e-06	6.4e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HTR2A—Alzheimer's disease	4.13e-06	6.38e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PPARG—Alzheimer's disease	4.04e-06	6.24e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—LPL—Alzheimer's disease	4.03e-06	6.23e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CALM1—Alzheimer's disease	4e-06	6.19e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—APOE—Alzheimer's disease	3.99e-06	6.16e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—INS—Alzheimer's disease	3.96e-06	6.12e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CAV1—Alzheimer's disease	3.95e-06	6.11e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CALM1—Alzheimer's disease	3.92e-06	6.06e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—LEP—Alzheimer's disease	3.91e-06	6.04e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—APOE—Alzheimer's disease	3.91e-06	6.04e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CALM1—Alzheimer's disease	3.9e-06	6.03e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CALM1—Alzheimer's disease	3.89e-06	6.01e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—LEP—Alzheimer's disease	3.89e-06	6.01e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—APOE—Alzheimer's disease	3.89e-06	6.01e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—LEP—Alzheimer's disease	3.88e-06	5.99e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—APOE—Alzheimer's disease	3.88e-06	5.99e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CAV1—Alzheimer's disease	3.87e-06	5.99e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PPARGC1A—Alzheimer's disease	3.86e-06	5.96e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CAV1—Alzheimer's disease	3.85e-06	5.96e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CALM1—Alzheimer's disease	3.85e-06	5.95e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CAV1—Alzheimer's disease	3.84e-06	5.94e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—APOE—Alzheimer's disease	3.84e-06	5.93e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—LEP—Alzheimer's disease	3.84e-06	5.93e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—HMOX1—Alzheimer's disease	3.84e-06	5.93e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CAV1—Alzheimer's disease	3.8e-06	5.88e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ESR1—Alzheimer's disease	3.73e-06	5.77e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ESR1—Alzheimer's disease	3.71e-06	5.74e-05	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—AKT1—Alzheimer's disease	3.7e-06	5.72e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ESR1—Alzheimer's disease	3.7e-06	5.72e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—F2—Alzheimer's disease	3.69e-06	5.7e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CASP3—Alzheimer's disease	3.67e-06	5.67e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—F2—Alzheimer's disease	3.67e-06	5.67e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ESR1—Alzheimer's disease	3.67e-06	5.66e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—F2—Alzheimer's disease	3.66e-06	5.65e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—IL6—Alzheimer's disease	3.65e-06	5.63e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PPARGC1A—Alzheimer's disease	3.63e-06	5.61e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—MTHFR—Alzheimer's disease	3.63e-06	5.61e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—F2—Alzheimer's disease	3.62e-06	5.6e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—HMOX1—Alzheimer's disease	3.62e-06	5.59e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NOTCH1—Alzheimer's disease	3.61e-06	5.58e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PPARGC1A—Alzheimer's disease	3.6e-06	5.57e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NOTCH1—Alzheimer's disease	3.59e-06	5.55e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—HMOX1—Alzheimer's disease	3.59e-06	5.54e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NOTCH1—Alzheimer's disease	3.58e-06	5.53e-05	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AKT1—Alzheimer's disease	3.55e-06	5.48e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NOTCH1—Alzheimer's disease	3.54e-06	5.48e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CASP3—Alzheimer's disease	3.51e-06	5.43e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—LPL—Alzheimer's disease	3.51e-06	5.42e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—IL6—Alzheimer's disease	3.49e-06	5.39e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PPARG—Alzheimer's disease	3.47e-06	5.37e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—NOS3—Alzheimer's disease	3.47e-06	5.37e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—INS—Alzheimer's disease	3.41e-06	5.27e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CALM1—Alzheimer's disease	3.39e-06	5.24e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GSK3B—Alzheimer's disease	3.39e-06	5.23e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—APOE—Alzheimer's disease	3.38e-06	5.22e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MAPK8—Alzheimer's disease	3.37e-06	5.21e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GSK3B—Alzheimer's disease	3.37e-06	5.21e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AKT1—Alzheimer's disease	3.36e-06	5.2e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CREB1—Alzheimer's disease	3.36e-06	5.19e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GSK3B—Alzheimer's disease	3.36e-06	5.19e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CAV1—Alzheimer's disease	3.35e-06	5.17e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CREB1—Alzheimer's disease	3.34e-06	5.16e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—INS—Alzheimer's disease	3.34e-06	5.16e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CREB1—Alzheimer's disease	3.33e-06	5.15e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GSK3B—Alzheimer's disease	3.33e-06	5.14e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—INS—Alzheimer's disease	3.32e-06	5.13e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—INS—Alzheimer's disease	3.31e-06	5.12e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—LPL—Alzheimer's disease	3.31e-06	5.11e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CREB1—Alzheimer's disease	3.3e-06	5.1e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCL2—Alzheimer's disease	3.29e-06	5.08e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—INS—Alzheimer's disease	3.28e-06	5.07e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—LPL—Alzheimer's disease	3.28e-06	5.07e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCL2—Alzheimer's disease	3.27e-06	5.05e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCL2—Alzheimer's disease	3.26e-06	5.04e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IGF1—Alzheimer's disease	3.23e-06	4.99e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MAPK8—Alzheimer's disease	3.23e-06	4.99e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCL2—Alzheimer's disease	3.23e-06	4.99e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AKT1—Alzheimer's disease	3.22e-06	4.98e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IGF1—Alzheimer's disease	3.21e-06	4.97e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IGF1—Alzheimer's disease	3.2e-06	4.95e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTGS2—Alzheimer's disease	3.18e-06	4.91e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IGF1—Alzheimer's disease	3.17e-06	4.9e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—MTHFR—Alzheimer's disease	3.16e-06	4.88e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VEGFA—Alzheimer's disease	3.11e-06	4.81e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—NOS3—Alzheimer's disease	2.99e-06	4.62e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VEGFA—Alzheimer's disease	2.98e-06	4.61e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—MTHFR—Alzheimer's disease	2.98e-06	4.6e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CALM1—Alzheimer's disease	2.95e-06	4.56e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—MTHFR—Alzheimer's disease	2.95e-06	4.56e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—APOE—Alzheimer's disease	2.94e-06	4.55e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PPARG—Alzheimer's disease	2.94e-06	4.55e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NOS3—Alzheimer's disease	2.93e-06	4.53e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CAV1—Alzheimer's disease	2.92e-06	4.5e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NOS3—Alzheimer's disease	2.91e-06	4.5e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NOS3—Alzheimer's disease	2.9e-06	4.49e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—INS—Alzheimer's disease	2.89e-06	4.46e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NOS3—Alzheimer's disease	2.88e-06	4.45e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TGFB1—Alzheimer's disease	2.86e-06	4.42e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CALM1—Alzheimer's disease	2.78e-06	4.3e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—APOE—Alzheimer's disease	2.77e-06	4.28e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CALM1—Alzheimer's disease	2.76e-06	4.26e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—APOE—Alzheimer's disease	2.75e-06	4.25e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CAV1—Alzheimer's disease	2.75e-06	4.25e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TGFB1—Alzheimer's disease	2.74e-06	4.23e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTGS2—Alzheimer's disease	2.73e-06	4.22e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CAV1—Alzheimer's disease	2.72e-06	4.21e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PPARG—Alzheimer's disease	2.56e-06	3.96e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—NOS3—Alzheimer's disease	2.53e-06	3.91e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—INS—Alzheimer's disease	2.51e-06	3.88e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AKT1—Alzheimer's disease	2.51e-06	3.88e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AKT1—Alzheimer's disease	2.5e-06	3.86e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AKT1—Alzheimer's disease	2.49e-06	3.85e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CASP3—Alzheimer's disease	2.49e-06	3.84e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CASP3—Alzheimer's disease	2.47e-06	3.82e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL6—Alzheimer's disease	2.47e-06	3.82e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CASP3—Alzheimer's disease	2.47e-06	3.81e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AKT1—Alzheimer's disease	2.47e-06	3.81e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL6—Alzheimer's disease	2.46e-06	3.8e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL6—Alzheimer's disease	2.45e-06	3.79e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CASP3—Alzheimer's disease	2.44e-06	3.77e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL6—Alzheimer's disease	2.43e-06	3.75e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PPARG—Alzheimer's disease	2.42e-06	3.73e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PPARG—Alzheimer's disease	2.39e-06	3.7e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—INS—Alzheimer's disease	2.37e-06	3.66e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—Alzheimer's disease	2.35e-06	3.64e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—INS—Alzheimer's disease	2.35e-06	3.63e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTGS2—Alzheimer's disease	2.31e-06	3.58e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAPK8—Alzheimer's disease	2.29e-06	3.53e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AKT1—Alzheimer's disease	2.28e-06	3.52e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAPK8—Alzheimer's disease	2.27e-06	3.51e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AKT1—Alzheimer's disease	2.27e-06	3.5e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAPK8—Alzheimer's disease	2.27e-06	3.5e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AKT1—Alzheimer's disease	2.26e-06	3.49e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—Alzheimer's disease	2.25e-06	3.48e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAPK8—Alzheimer's disease	2.24e-06	3.47e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AKT1—Alzheimer's disease	2.24e-06	3.46e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—NOS3—Alzheimer's disease	2.2e-06	3.41e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL6—Alzheimer's disease	2.15e-06	3.33e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VEGFA—Alzheimer's disease	2.11e-06	3.26e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VEGFA—Alzheimer's disease	2.1e-06	3.24e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VEGFA—Alzheimer's disease	2.09e-06	3.23e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—NOS3—Alzheimer's disease	2.08e-06	3.21e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VEGFA—Alzheimer's disease	2.07e-06	3.2e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL6—Alzheimer's disease	2.06e-06	3.19e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—NOS3—Alzheimer's disease	2.06e-06	3.18e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTGS2—Alzheimer's disease	2.02e-06	3.12e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AKT1—Alzheimer's disease	1.99e-06	3.07e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TGFB1—Alzheimer's disease	1.94e-06	2.99e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TGFB1—Alzheimer's disease	1.93e-06	2.98e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TGFB1—Alzheimer's disease	1.92e-06	2.97e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AKT1—Alzheimer's disease	1.9e-06	2.94e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TGFB1—Alzheimer's disease	1.9e-06	2.94e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTGS2—Alzheimer's disease	1.9e-06	2.94e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTGS2—Alzheimer's disease	1.88e-06	2.91e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AKT1—Alzheimer's disease	1.6e-06	2.47e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—Alzheimer's disease	1.59e-06	2.46e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—Alzheimer's disease	1.59e-06	2.45e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—Alzheimer's disease	1.58e-06	2.44e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—Alzheimer's disease	1.57e-06	2.42e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6—Alzheimer's disease	1.46e-06	2.26e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6—Alzheimer's disease	1.45e-06	2.24e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6—Alzheimer's disease	1.45e-06	2.24e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6—Alzheimer's disease	1.43e-06	2.21e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AKT1—Alzheimer's disease	1.37e-06	2.12e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKT1—Alzheimer's disease	1.35e-06	2.08e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKT1—Alzheimer's disease	1.34e-06	2.07e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKT1—Alzheimer's disease	1.34e-06	2.06e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKT1—Alzheimer's disease	1.32e-06	2.04e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AKT1—Alzheimer's disease	1.16e-06	1.8e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AKT1—Alzheimer's disease	1.01e-06	1.57e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKT1—Alzheimer's disease	9.55e-07	1.48e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKT1—Alzheimer's disease	9.47e-07	1.46e-05	CbGpPWpGaD
